When Lilly released results of its Phase III Expedition trials two months ago, the findings indicated that cognitive decline was slowed by 42 percent in patients in the early stages of the disease in one trial, and there were also positive signs from another trial, although the showing was not statistically significant.
FORBES: Eli Lilly To Run Another Phase 3 Trial For Alzheimer's Med